{"filing":{"accession_number":"0001140361-26-031423","cik":"0001368514","ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"ef20079311_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/ef20079311_8k.htm"},"events":[{"id":24421,"run_id":22127,"accession_number":"0001140361-26-031423","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"ADMA Biologics issued a press release on August 5, 2026 announcing its financial results for the three months ended June 30, 2026, including total revenue of $124.4 million (up 2% YoY), GAAP net income of $37.8 million (up 11% YoY), and GAAP basic EPS of $0.17 (up 17% YoY). The filing explicitly states this is Item 2.02 disclosure of results of operations and financial condition, with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24965,"accession_number":"0001140361-26-031423","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ADMA Biologics issued a press release on August 5, 2026 announcing its financial results for the three months ended June 30, 2026, including total revenue of $124.4 million (up 2% YoY), GAAP net income of $37.8 million (up 11% YoY), and GAAP basic EPS of $0.17 (up 17% YoY). The filing explicitly states this is Item 2.02 disclosure of results of operations and financial condition, with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:34:15.524996+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24965,"accession_number":"0001140361-26-031423","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ADMA Biologics issued a press release on August 5, 2026 announcing its financial results for the three months ended June 30, 2026, including total revenue of $124.4 million (up 2% YoY), GAAP net income of $37.8 million (up 11% YoY), and GAAP basic EPS of $0.17 (up 17% YoY). The filing explicitly states this is Item 2.02 disclosure of results of operations and financial condition, with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:34:15.524996+00:00","company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","filing_date":"2026-08-05"}]}